Zydus Cadila gets USFDA nod for anti-depression drug

PTI New Delhi | Updated on January 08, 2018

Zydus Cadila has received final approval from the US health regulator to market desvenlafaxine extended release tablets, used to treat depression.

Approval from the United States Food and Drug Administration (USFDA) is to market desvenlafaxine extended release tablets in the strengths of 50 mg and 100 mg, Zydus Cadila said in a BSE filing today.

The drug will be manufactured at the group’s formulations manufacturing facility at Moraiya in Ahmedabad, it added.

The group now has more than 160 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since the commencement of its filing process, it added.

Shares of Cadila Healthcare, the company’s listed entity, were today trading 1.41 per cent higher at Rs 498.30 on the BSE.

Published on October 12, 2017

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like